Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

The Lancet Infectious Diseases - Tập 15 Số 5 - Trang 565-580 - 2015
Mélanie Drolet1,2, Élodie Bénard1,2, Marie‐Claude Boily1,3,2, Hammad Ali4, Louise Baandrup5, Heidi M. Bauer6, Simon Beddows7, Jacques Brisson1,2, Julia Brotherton8,9, Teresa Cummings10, Basil Donovan4, Christopher K. Fairley11,12, Elaine W. Flagg13, Margaret Johnson14, Jessica A. Kahn15, Kimberley Kavanagh16, Susanne K. Kjær17,5, Erich V. Kliewer18,19,20, Philippe Lemieux-Mellouki1,2, Lauri E. Markowitz13, Aminata Mboup1, David Mesher21, Linda M. Niccolai22, Jeannie Oliphant23, Kevin G. Pollock24, Kate Soldan21, Pam Sonnenberg14, Sepehr N. Tabrizi25,26,27, Clare Tanton14, Marc Brisson1,3,2
1Centre de recherche du CHU de Québec, Québec, QC, Canada
2Département de médecine sociale et préventive, université Laval, Québec, Qc, Canada
3Department of Infectious Disease Epidemiology, Imperial College London, London, UK
4The Kirby Institute, University of New South Wales, Sydney, NSW, Australia
5Unit of Virus, Lifestyle and Genes, The Danish Cancer Society Research Centre, Copenhagen, Denmark
6STD Control Branch of the California Department of Public Health, Richmond, CA, USA
7Virus Reference Department, Public Health England, London, UK
8Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia
9National HPV Vaccination Program Register, Victorian Cytology Service, East Melbourne, Melbourne, VIC, Australia
10Department of Pediatrics Indiana University School of Medicine Indianapolis IN USA
11Central Clinical School, Monash University, Alfred Hospital, Melbourne, VIC, Australia
12Melbourne Sexual Health Centre, Melbourne, VIC, Australia
13National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA, USA
14Research Department of Infection and Population Health, University College London, London, UK
15Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH, USA
16Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK
17Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
18Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada
19Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada
20Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, MB, Canada
21HIV and STI Department, Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK
22Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, CT, USA
23Auckland Sexual Health Service, Auckland, New Zealand
24Health Protection Scotland, Glasgow, UK
25Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, VIC, Australia
26Murdoch Childrens Research Institute, Parkville, Vic, Australia
27Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, VIC, Australia

Tóm tắt

Từ khóa


Tài liệu tham khảo

Ladner, 2014, Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009–2013, BMC Public Health, 14, 670, 10.1186/1471-2458-14-670

Munoz, 2003, Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med, 348, 518, 10.1056/NEJMoa021641

Garland, 2009, Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine, J Infect Dis, 199, 805, 10.1086/597071

Markowitz, 2012, Human papillomavirus vaccine introduction-the first five years, Vaccine, 30, F139, 10.1016/j.vaccine.2012.05.039

2011, Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011, MMWR Morb Mortal Wkly Rep, 60, 1705

Georgousakis, 2012, Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study, Lancet Infect Dis, 12, 627, 10.1016/S1473-3099(12)70031-2

Paul, 2014, Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program, Vaccine, 32, 320, 10.1016/j.vaccine.2013.11.070

Garland, 2007, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, N Engl J Med, 356, 1928, 10.1056/NEJMoa061760

Paavonen, 2009, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, Lancet, 374, 301, 10.1016/S0140-6736(09)61248-4

Wheeler, 2012, Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol, 13, 100, 10.1016/S1470-2045(11)70287-X

Wheeler, 2009, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years, J Infect Dis, 199, 936, 10.1086/597309

de Sanjose, 2010, Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study, Lancet Oncol, 11, 1048, 10.1016/S1470-2045(10)70230-8

Malagon, 2012, Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis, Lancet Infect Dis, 12, 781, 10.1016/S1473-3099(12)70187-1

Brisson, 2009, Economic evaluation of human papillomavirus vaccination in developed countries, Public Health Genomics, 12, 343, 10.1159/000214924

Fesenfeld, 2013, Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review, Vaccine, 31, 3786, 10.1016/j.vaccine.2013.06.060

Jit, 2014, Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study, Lancet Glob Health, 2, e406, 10.1016/S2214-109X(14)70237-2

Van de Velde, 2012, Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis, J Natl Cancer Inst, 104, 1712, 10.1093/jnci/djs395

Brisson, 2011, Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity, J Infect Dis, 204, 372, 10.1093/infdis/jir285

Choi, 2010, Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom, Vaccine, 28, 4091, 10.1016/j.vaccine.2009.09.125

Baussano, 2014, Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model, Infect Agent Cancer, 9, 4, 10.1186/1750-9378-9-4

Bogaards, 2011, Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models, PLoS Med, 8, e1001147, 10.1371/journal.pmed.1001147

Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700

Rosner, 1995

DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Deeks

2011

Berlin, 1993, Meta-analysis of epidemiologic dose-response data, Epidemiology, 4, 218, 10.1097/00001648-199305000-00005

Cummings, 2012, Reduction of HPV infections through vaccination among at-risk urban adolescents, Vaccine, 30, 5496, 10.1016/j.vaccine.2012.06.057

Kahn, 2012, Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction, Pediatrics, 130, e249, 10.1542/peds.2011-3587

Tabrizi, 2012, Fall in human papillomavirus prevalence following a national vaccination program, J Infect Dis, 206, 1645, 10.1093/infdis/jis590

Markowitz, 2013, Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010, J Infect Dis, 208, 385, 10.1093/infdis/jit192

Mesher, 2013, Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England, Vaccine, 32, 26, 10.1016/j.vaccine.2013.10.085

Sonnenberg, 2013, Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal), Lancet, 382, 1795, 10.1016/S0140-6736(13)61947-9

Kavanagh, 2014, Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types, Br J Cancer, 110, 2804, 10.1038/bjc.2014.198

Oliphant, 2011, Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services, N Z Med J, 124, 51

Bauer, 2012, Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010, Am J Public Health, 102, 833, 10.2105/AJPH.2011.300465

Kliewer E, Mahmud SM, Demers AA, Lambert P, Musto G. Quadrivalent HPV vaccination and the incidence of anogenital warts in Manitoba, Canada. 28th International Papillomavirus Conference; San Juan, Puerto Rico; Nov 30–Dec 6, 2012. Abstract E07-663.

Leval, 2012, Incidence of genital warts in sweden before and after quadrivalent human papillomavirus vaccine availability, J Infect Dis, 206, 860, 10.1093/infdis/jis405

Ali, 2013, Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data, BMJ, 346, f2032, 10.1136/bmj.f2032

Baandrup, 2013, Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program, Sex Transm Dis, 40, 130, 10.1097/OLQ.0b013e31827bd66b

Howell-Jones, 2013, Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study, J Infect Dis, 208, 1397, 10.1093/infdis/jit361

Flagg, 2013, Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination, Am J Public Health, 103, 1428, 10.2105/AJPH.2012.301182

Mikolajczyk, 2013, Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany–an ecologic study, Sex Transm Dis, 40, 28, 10.1097/OLQ.0b013e3182756efd

Nsouli-Maktabi, 2013, Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine, MSMR, 20, 17

Sando, 2014, A reduced national incidence of anogenital warts in young Danish Men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women—an ecological study, Acta Derm Venereol, 94, 288, 10.2340/00015555-1721

Brotherton, 2011, Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study, Lancet, 377, 2085, 10.1016/S0140-6736(11)60551-5

Niccolai, 2013, Declining rates of high-grade cervical lesions in young women in Connecticut, 2008–2011, Cancer Epidemiol Biomarkers Prev, 22, 1446, 10.1158/1055-9965.EPI-13-0272

Crowe, 2014, Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia, BMJ, 348, g1458, 10.1136/bmj.g1458

Leval, 2013, Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study, J Natl Cancer Inst, 105, 469, 10.1093/jnci/djt032

Blomberg, 2013, Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark, Clin Infect Dis, 57, 929, 10.1093/cid/cit436

Gertig, 2013, Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study, BMC Med, 11, 227, 10.1186/1741-7015-11-227

Mercer, 2013, Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal), Lancet, 382, 1781, 10.1016/S0140-6736(13)62035-8

Wellings, 2006, Sexual behaviour in context: a global perspective, Lancet, 368, 1706, 10.1016/S0140-6736(06)69479-8

Mori, 2011, Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers, Cancer Sci, 102, 1223, 10.1111/j.1349-7006.2011.01922.x

Naud, 2014, Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination, Hum Vaccin Immunother, 10, 2147, 10.4161/hv.29532

Pagliusi, 2004, Efficacy and other milestones for human papillomavirus vaccine introduction, Vaccine, 23, 569, 10.1016/j.vaccine.2004.07.046

Steens, 2013, Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: implications for future impact on prevention, Int J Cancer, 132, 932, 10.1002/ijc.27671

Kliewer, 2013, Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada, Vaccine, 32, 33, 10.1016/j.vaccine.2013.10.082

Spencer, 2014, Sociodemographic factors predicting mother's cervical screening and daughter's HPV vaccination uptake, J Epidemiol Community Health, 68, 571, 10.1136/jech-2013-202629

Jemal, 2013, Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels, J Natl Cancer Inst, 105, 175, 10.1093/jnci/djs491

Brisson, 2011, Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11, Sex Transm Infect, 87, 41, 10.1136/sti.2010.044412

de Sanjose, 2007, Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis, Lancet Infect Dis, 7, 453, 10.1016/S1473-3099(07)70158-5

Clifford, 2003, Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis, Br J Cancer, 89, 101, 10.1038/sj.bjc.6601024

Bruni, 2010, Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings, J Infect Dis, 202, 1789, 10.1086/657321

Adler, 2012, Increased regression and decreased incidence of HPV-related cervical lesions among HIV-infected women on HAART, AIDS, 26, 1645, 10.1097/QAD.0b013e32835536a3

Denny, 2013, Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study, Vaccine, 31, 5745, 10.1016/j.vaccine.2013.09.032

Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 15 Số 5

565-580

Thông tin tác giả